RVMD

Company Overview — What Does Revolution Medicines, Inc. Do?

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Revolution Medicines, Inc. (RVMD) is classified as a large-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Mark A. Goldsmith and employs approximately 250 people. With a market capitalization of $19.5B, RVMD is one of the prominent companies in the Healthcare sector.

Revolution Medicines, Inc. (RVMD) Stock Rating — Reduce (April 2026)

As of April 2026, Revolution Medicines, Inc. receives a Reduce rating with a composite score of 38.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.RVMD ranks #2,433 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Revolution Medicines, Inc. ranks #300 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

RVMD Stock Price and 52-Week Range

Revolution Medicines, Inc. (RVMD) currently trades at $97.90. The stock gained $1.68 (1.7%) in the most recent trading session. The 52-week high for RVMD is $124.49, which means the stock is currently trading -21.4% from its annual peak. The 52-week low is $29.17, putting the stock 235.6% above its annual trough. Recent trading volume was 2.0M shares, reflecting moderate market activity.

Is RVMD Overvalued or Undervalued? — Valuation Analysis

Revolution Medicines, Inc. (RVMD) carries a value factor score of 27/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 11.70x, versus the sector average of 2.75x.

At current multiples, Revolution Medicines, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Revolution Medicines, Inc. Profitability — ROE, Margins, and Quality Score

Revolution Medicines, Inc. (RVMD) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -56.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -39.2% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

RVMD Debt, Balance Sheet, and Financial Health

Revolution Medicines, Inc. has a debt-to-equity ratio of 44.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 7.14x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $217M.

RVMD has a beta of 1.00, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Revolution Medicines, Inc. is 54/100, reflecting average volatility within the normal range for its sector.

Revolution Medicines, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Revolution Medicines, Inc. reported revenue of $0 and earnings per share (EPS) of $-5.95. Net income for the quarter was $-923M. Operating income came in at $-996M.

In FY 2025, Revolution Medicines, Inc. reported revenue of $0 and earnings per share (EPS) of $-5.95. Net income for the quarter was $-1.13B. Operating income came in at $-1.18B.

In Q3 2025, Revolution Medicines, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.61. Net income for the quarter was $-305M. Operating income came in at $-315M.

In Q2 2025, Revolution Medicines, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.31. Net income for the quarter was $-248M. Operating income came in at $-265M.

Over the past 8 quarters, Revolution Medicines, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing RVMD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

RVMD Dividend Yield and Income Analysis

Revolution Medicines, Inc. (RVMD) does not currently pay a dividend. This is common among growth-oriented companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

RVMD Momentum and Technical Analysis Profile

Revolution Medicines, Inc. (RVMD) has a momentum factor score of 75/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 10/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

RVMD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Revolution Medicines, Inc. (RVMD) ranks #300 out of 838 stocks based on the Blank Capital composite score. This places RVMD in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing RVMD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full RVMD vs S&P 500 (SPY) comparison to assess how Revolution Medicines, Inc. stacks up against the broader market across all factor dimensions.

RVMD Next Earnings Date

No upcoming earnings date has been announced for Revolution Medicines, Inc. (RVMD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy RVMD? — Investment Thesis Summary

The quantitative profile for Revolution Medicines, Inc. suggests caution. The quality score of 24/100 flags below-average profitability. The value score of 27/100 indicates premium valuation. Price momentum is positive at 75/100, suggesting the trend favors buyers.

In summary, Revolution Medicines, Inc. (RVMD) earns a Reduce rating with a composite score of 38.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on RVMD stock.

Related Resources for RVMD Investors

Explore more research and tools: RVMD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare RVMD head-to-head with peers: RVMD vs AZN, RVMD vs SLGL, RVMD vs VMD.